Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer.

[1]  J. Brahmer,et al.  Immune Checkpoint Therapy in Non–Small Cell Lung Cancer , 2016, Cancer journal.

[2]  D. R. Lewis,et al.  Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system , 2014, Cancer.

[3]  P. Iyengar,et al.  Locally Advanced Lung Cancer: An Optimal Setting for Vaccines and Other Immunotherapies , 2013, Cancer journal.

[4]  R. Mcgarry,et al.  Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. , 2013, International journal of radiation oncology, biology, physics.

[5]  W. Curran,et al.  Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Andrea Bezjak,et al.  Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.

[7]  A. Cazes,et al.  Microscopic residual disease after resection for lung cancer: a multifaceted but poor factor of prognosis. , 2010, The Annals of thoracic surgery.

[8]  Lech Papiez,et al.  Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. , 2009, International journal of radiation oncology, biology, physics.

[9]  J. Daurès,et al.  Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Walter J Curran,et al.  Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Tae Hyun Kim,et al.  Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. , 2005, Radiology.

[12]  T. Araki,et al.  Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma , 2004, Cancer.

[13]  M T Munley,et al.  Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. , 2001, International journal of radiation oncology, biology, physics.

[14]  S. Kudoh,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R K Ten Haken,et al.  Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. , 1999, Lung cancer.

[16]  K. Hayakawa,et al.  Risk factors for severe radiation pneumonitis in lung cancer. , 1999, Japanese journal of clinical oncology.

[17]  D. Gandara,et al.  Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Watanabe,et al.  Age factor relevant to the development of radiation pneumonitis in radiotherapy of lung cancer. , 1988, International journal of radiation oncology, biology, physics.

[19]  S Kramer,et al.  A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non‐oat‐cell carcinoma of the lung. Preliminary report by the radiation therapy oncology group , 1980, Cancer.

[20]  Ashutosh Kumar Singh,et al.  Primary Study Endpoint Analysis for NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-Small Cell Lung Cancer (NSCLC) , 2016 .

[21]  R. Mcgarry,et al.  Risk for fatal pulmonary hemorrhage does not appear to be increased following dose escalation using stereotactic body radiotherapy (SBRT) in locally advanced non-small cell lung cancer (NSCLC). , 2013, Journal of radiosurgery and SBRT.

[22]  S. Larson,et al.  An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. , 2002, The Annals of thoracic surgery.

[23]  R. Snijder,et al.  Survival in resected stage I lung cancer with residual tumor at the bronchial resection margin. , 1998, The Annals of thoracic surgery.

[24]  I. Lax,et al.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. , 1995, Acta oncologica.

[25]  I. Lax,et al.  Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. , 1994, Acta oncologica.

[26]  Hao Wu,et al.  Open Access Research , 2022 .